Ardelyx, Inc. (NASDAQ:ARDX – Get Rating) – Equities research analysts at Wedbush cut their FY2026 earnings estimates for Ardelyx in a note issued to investors on Friday, May 6th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings of $0.35 per share for the year, down from their prior forecast of $0.40. Ardelyx (NASDAQ:ARDX – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. Ardelyx had a negative net margin of 3,843.36% and a negative return on equity of 163.07%. During the same quarter in the previous year, the business earned ($0.34) EPS.
ARDX has been the topic of a number of other research reports. Cantor Fitzgerald lowered shares of Ardelyx from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $7.00 to $1.00 in a research note on Friday. Jefferies Financial Group upgraded shares of Ardelyx from a “hold” rating to a “buy” rating and lifted their price objective for the company from $1.00 to $5.00 in a research note on Wednesday, March 2nd. StockNews.com initiated coverage on shares of Ardelyx in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Zacks Investment Research lowered shares of Ardelyx from a “buy” rating to a “hold” rating in a research note on Tuesday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.84.
ARDX opened at $0.81 on Monday. The stock has a market capitalization of $116.75 million, a price-to-earnings ratio of -0.58 and a beta of 1.84. The firm’s 50 day moving average price is $0.95. Ardelyx has a 52-week low of $0.58 and a 52-week high of $2.15.
Several large investors have recently modified their holdings of ARDX. Morgan Stanley increased its stake in Ardelyx by 1,383.0% during the second quarter. Morgan Stanley now owns 197,496 shares of the biopharmaceutical company’s stock valued at $1,496,000 after purchasing an additional 184,179 shares during the last quarter. Invesco Ltd. increased its stake in Ardelyx by 93.6% during the second quarter. Invesco Ltd. now owns 32,482 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 15,703 shares during the last quarter. SG Americas Securities LLC bought a new stake in Ardelyx during the third quarter valued at $64,000. BlackRock Inc. increased its stake in Ardelyx by 3.8% during the third quarter. BlackRock Inc. now owns 6,455,902 shares of the biopharmaceutical company’s stock valued at $8,522,000 after purchasing an additional 237,006 shares during the last quarter. Finally, Barclays PLC increased its stake in Ardelyx by 213.2% during the third quarter. Barclays PLC now owns 37,217 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 25,333 shares during the last quarter. Institutional investors and hedge funds own 32.35% of the company’s stock.
Ardelyx Company Profile (Get Rating)
Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia.